In conclusion, this study determined the main pathways and genes associated with the PTEN mutation in ccRCC, which may facilitate the development of the PTEN mutation to improve ccRCC risk prediction through the development of therapeutic strategies against such special subtypes of ccRCC. Here, PTEN is linked to nonpapillary renal cell carcinoma.